Trial intelligence / Profile preview

GEODE-I: OBV/PTV/r ± DSV ± RBV in HCV with Prior HCC

NCT02504099Phase 3Terminated

Sponsor
AbbVie Inc.
Start
Jul 2015
Primary completion
Sep 2016
Modality
Allosteric Modulators, Orthosteric Ligands
01

Overview

A Phase 3 trial of ombitasvir, paritaprevir, dasabuvir in hepatitis C (HCV), sponsored by AbbVie Inc.. Started Jul 2015; status: terminated.

02

Drugs

ombitasvirparitaprevirdasabuvir
03

Conditions

hepatitis C (HCV)

Beyond the preview

Go deeper on NCT02504099.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT02504099.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call